Fine-needle aspiration (FNA) has high sensitivity and specificity in distinguishing benign from malignant thyroid lesions. However, in 5-20% of the cases belonging to the indeterminate cytology categories (follicular neoplasms and atypia of undetermined significance) it is not possible to discriminate between benign and malignant tumours. As a consequence of this limitation, patients with such diagnoses have to be submitted to diagnostic rather than to curative thyroid surgery.
Fine-needle aspiration (FNA) has high sensitivity and specificity in distinguishing benign from malignant thyroid lesions. However, in 5-20% of the cases belonging to the indeterminate cytology categories (follicular neoplasms and atypia of undetermined significance) it is not possible to discriminate between benign and malignant tumours. As a consequence of this limitation, patients with such diagnoses have to be submitted to diagnostic rather than to curative thyroid surgery.
A proteína RAC1b está fortemente associada ao tecido cancerígeno e tem sido apontada como um alvo promissor para a intervenção terapêutica em certos subgrupos de tumores do pâncreas, mama, cólon e pulmão. O presente estudo assinala a inclusão dos carcinomas da tiróide de origem folicular nesta lista, perspetivando-se a abertura de novas opções terapêuticas para as formas de doença mais avançada. O cancro da tiróide é a neoplasia endócrina maligna mais comum e a sua incidência tem vindo a aumentar a nível mundial ao longo das últimas décadas.
Catarina Tavares1,2,3, Maria João Coelho1,2,4, Miguel Melo1,2,5,6, Adriana Gaspar da Rocha1,2,7, Ana Pestana1,2,3, Rui Batista1,2,3, Catarina Salgado1,2, Catarina Eloy1,2, Luciana Ferreira1,2,3, Elisabete Rios3,8,9, Manuel Sobrinho-Simões1,2,3,8,9 and Paula Soares1,2,3,8
1-Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto;
Tumour initiation results from a mutation acquired, for example, in a cell proliferation-regulating oncogene, for example the MAP kinase BRAF in melanoma, thyroid, ovarian and colorectal cancer. As a protective response to this initial proliferative stimulus, tissues induce a growth-arrest program termed oncogene-induced senescence (OIS). It remains largely unknown by which mechanisms the initiated cells eventually escape from the dormant OIS state.
Tumour initiation results from a mutation acquired, for example, in a cell proliferation-regulating oncogene, for example the MAP kinase BRAF in melanoma, thyroid, ovarian and colorectal cancer. As a protective response to this initial proliferative stimulus, tissues induce a growth-arrest program termed oncogene-induced senescence (OIS). It remains largely unknown by which mechanisms the initiated cells eventually escape from the dormant OIS state.
The familial forms of non-medullary thyroid carcinoma (FNMTC) represent 5% of thyroid neoplasms. To date, three FNMTC susceptibility genes have been identified (NKX2-1, DICER1 and SRGAP1). This study represents the first evidence of involvement of a germline FOXE1 rare variant in FNMTC etiology. This gene, which encodes the FOXE1 transcription factor involved in the morphogenesis and differentiation of the thyroid, may represent a novel susceptibility gene for this familial thyroid disease.
As formas familiares de carcinoma não-medular da tiróide (FNMTC) representam cerca de 5% de todas as neoplasias da glândula tiroideia. Até à data, foram identificados três genes de susceptibilidade para o FNMTC (NKX2-1, DICER1 e SRGAP1). Este estudo apresentou, pela primeira vez, evidência do envolvimento a nível germinal de uma variante rara no gene FOXE1, na etiologia do FNMTC.
